Blood Tests for Collagen Fragments Can Track How Fast Your Liver Is Scarring
Procollagen peptide levels in the blood rise with the severity of liver scarring, offering a potential non-invasive alternative to liver biopsy for monitoring fibrosis progression.
Quick Facts
What This Study Found
Blood levels of procollagen peptides — particularly procollagen type III N-propeptide (PIIINP) — tracked with the severity of liver scarring in both schistosomiasis and alcoholic liver disease. PIIINP was significantly elevated in all schistosomiasis patient groups compared to healthy controls (p<0.01), and patients with worse scarring on biopsy had higher PIIINP levels (p<0.05). In alcoholic patients, PIIINP was even higher and rose with disease severity.
Interestingly, procollagen type I C-propeptide was only elevated during early infection and decreased as disease progressed, suggesting it reflects early-stage collagen production while PIIINP better captures ongoing active fibrosis. Different collagen markers appeared to track different aspects of the scarring process — synthesis versus degradation.
Key Numbers
n=100 (15 controls + 69 schistosomiasis + 16 alcoholic cirrhosis) · PIIINP elevated p<0.01 · higher histological grade = higher PIIINP p<0.05 · 30 liver biopsies
How They Did This
Cross-sectional study measuring serum concentrations of four collagen-related peptide markers (procollagen type III N-propeptide, procollagen type I C-propeptide, procollagen type IV C-propeptide, and collagen type VI) in healthy controls, three stages of schistosomiasis infection, and alcoholic cirrhosis patients. Correlated with liver biopsy histopathology and collagen histochemistry in 30 schistosomal patients.
Why This Research Matters
Liver fibrosis progresses silently and conventional liver tests don't reveal how active the scarring process is. Liver biopsy is invasive and only captures a small sample. Blood-based peptide biomarkers like procollagen propeptides could offer a non-invasive way to monitor fibrosis activity in real time — critical for the hundreds of millions of people worldwide with chronic liver disease from various causes.
The Bigger Picture
Non-invasive fibrosis assessment has become one of the most important goals in hepatology. This early 1990s study was part of the wave of research establishing procollagen peptides as fibrosis biomarkers — work that eventually led to today's widely used fibrosis scoring systems (FibroTest, ELF score) that include procollagen markers. Understanding how different collagen peptide fragments reflect different aspects of fibrosis (synthesis vs. degradation, early vs. late stage) has been essential for developing accurate non-invasive monitoring.
What This Study Doesn't Tell Us
Relatively small sample sizes across groups, especially controls (n=15) and alcoholic cirrhosis (n=16). Cross-sectional design cannot track how biomarker levels change over time in individual patients. The abstract was truncated, so some results regarding collagen type VI and type IV markers are not fully reported. The study is from 1992 and newer fibrosis markers have since been developed.
Questions This Raises
- ?How do procollagen peptide biomarkers compare to newer non-invasive fibrosis tools like FibroScan and the ELF score?
- ?Can serial procollagen measurements track treatment response in patients receiving anti-fibrotic therapy?
- ?Do different causes of liver disease produce distinct patterns of collagen peptide biomarker elevation?
Trust & Context
- Key Stat:
- p<0.01 Procollagen type III N-propeptide was significantly elevated in all schistosomiasis patient groups compared to healthy controls, with levels correlating to fibrosis severity
- Evidence Grade:
- This is an original observational study published in Hepatology with biopsy-correlated biomarker data. While the sample sizes are modest, the direct comparison of blood markers with tissue histology strengthens the findings.
- Study Age:
- Published in 1992 in Hepatology. This is a foundational study in the development of non-invasive fibrosis biomarkers. While newer and more sophisticated markers are now available, the procollagen peptide approach described here laid essential groundwork and remains part of modern fibrosis panels.
- Original Title:
- Serum procollagen peptides and collagen type VI for the assessment of activity and degree of hepatic fibrosis in schistosomiasis and alcoholic liver disease.
- Published In:
- Hepatology (Baltimore, Md.), 15(4), 637-44 (1992)
- Authors:
- Shahin, M, Schuppan, D, Waldherr, R, Risteli, J, Risteli, L, Savolainen, E R, Oesterling, C, Abdel Rahman, H M, el Sahly, A M, Abdel Razek, S M
- Database ID:
- RPEP-00248
Evidence Hierarchy
Watches what happens naturally without intervening.
What do these levels mean? →Frequently Asked Questions
What are procollagen peptides and why are they in the blood?
When your body makes collagen (the structural protein in scar tissue), it first produces a precursor called procollagen. During processing, small peptide fragments are clipped off and released into the bloodstream. When the liver is actively scarring, collagen production ramps up, and these procollagen peptide fragments increase in the blood — acting as a signal of active fibrosis.
Can a blood test replace liver biopsy for detecting fibrosis?
This study showed that blood levels of procollagen peptides correlate with fibrosis severity on biopsy. Since then, these markers have been incorporated into non-invasive fibrosis scoring systems that are widely used in clinical practice, reducing (though not completely eliminating) the need for liver biopsy.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-00248APA
Shahin, M; Schuppan, D; Waldherr, R; Risteli, J; Risteli, L; Savolainen, E R; Oesterling, C; Abdel Rahman, H M; el Sahly, A M; Abdel Razek, S M. (1992). Serum procollagen peptides and collagen type VI for the assessment of activity and degree of hepatic fibrosis in schistosomiasis and alcoholic liver disease.. Hepatology (Baltimore, Md.), 15(4), 637-44.
MLA
Shahin, M, et al. "Serum procollagen peptides and collagen type VI for the assessment of activity and degree of hepatic fibrosis in schistosomiasis and alcoholic liver disease.." Hepatology (Baltimore, 1992.
RethinkPeptides
RethinkPeptides Research Database. "Serum procollagen peptides and collagen type VI for the asse..." RPEP-00248. Retrieved from https://rethinkpeptides.com/research/shahin-1992-serum-procollagen-peptides-and
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.